Molecular targets in pituitary tumours (Q35730308)

9 August 2017

1 reference

title

Molecular targets in pituitary tumours (English)

1 reference

9 August 2017

2

Shlomo Melmed

1 reference

9 August 2017

Anthony P Heaney

1

1 reference

9 August 2017

language of work or name

English

0 references

publication date

1 April 2004

1 reference

9 August 2017

published in

Nature Reviews Cancer

1 reference

9 August 2017

volume

4

1 reference

9 August 2017

issue

4

1 reference

9 August 2017

page(s)

285-295

1 reference

Mechanisms for pituitary tumorigenesis: the plastic pituitary

9 August 2017

cites work

1 reference

Clinical impact of hyperprolactinaemia.

31 March 2020

1 reference

Medical management of prolactin-secreting pituitary adenomas

31 March 2020

1 reference

31 March 2020

1 reference

Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma

31 March 2020

1 reference

Positional cloning of the gene for multiple endocrine neoplasia-type 1

31 March 2020

1 reference

Mutations in the protein kinase A R1alpha regulatory subunit cause familial cardiac myxomas and Carney complex.

31 March 2020

1 reference

Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex.

31 March 2020

1 reference

The pathogenesis of pituitary tumours

31 March 2020

1 reference

Clinically nonfunctioning pituitary tumors are monoclonal in origin

31 March 2020

1 reference

Clonal origin of pituitary adenomas

31 March 2020

1 reference

Somatotroph hyperplasia. Successful treatment of acromegaly by removal of a pancreatic islet tumor secreting a growth hormone-releasing factor

31 March 2020

1 reference

Growth hormone-releasing hormone-producing tumors: clinical, biochemical, and morphological manifestations

31 March 2020

1 reference

Two G protein oncogenes in human endocrine tumors

31 March 2020

1 reference

G-Protein Oncogenes in Acromegaly

31 March 2020

1 reference

Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas

31 March 2020

1 reference

Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis

31 March 2020

1 reference

Management of pituitary tumors

31 March 2020

1 reference

Diagnosis and management of nonfunctioning pituitary tumors

31 March 2020

1 reference

Transsphenoidal microsurgery for Cushing disease. A report of 216 cases

31 March 2020

1 reference

Serum cortisol response to transsphenoidal surgery for Cushing disease

31 March 2020

1 reference

Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly

31 March 2020

1 reference

Long-term results in transsphenoidal removal of nonfunctioning pituitary adenomas

31 March 2020

1 reference

The long-term efficacy of conservative surgery and radiotherapy in the control of pituitary adenomas

31 March 2020

1 reference

Hormonal and metabolic effects of radiotherapy in acromegaly: long-term results in 128 patients followed in a single center

31 March 2020

1 reference

Primary medical therapy for acromegaly

31 March 2020

1 reference

31 March 2020

1 reference

Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors

31 March 2020

1 reference

31 March 2020

1 reference

31 March 2020

1 reference

The sensitivity of growth hormone and prolactin secretion to the somatostatin analogue SMS 201-995 in patients with prolactinomas and acromegaly

31 March 2020

1 reference

Octreotide treatment of acromegaly. A randomized, multicenter study

31 March 2020

1 reference

111Indium-pentetreotide pituitary scintigraphy and hormonal responses to octreotide in acromegalic patients

31 March 2020

1 reference

Somatostatin analogs in acromegaly

31 March 2020

1 reference

The pathophysiological consequences of somatostatin receptor internalization and resistance

31 March 2020

1 reference

Guidelines for acromegaly management

31 March 2020

1 reference

Molecular biology of somatostatin receptor subtypes

31 March 2020

1 reference

Functional association of somatostatin receptor subtypes 2 and 5 in inhibiting human growth hormone secretion.

31 March 2020

1 reference

SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile

31 March 2020

1 reference

SOM230: a new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone/insulin-like growth factor-I axis in rats, primates, and dogs

31 March 2020

1 reference

Induction of wild-type p53, Bax, and acidic endonuclease during somatostatin-signaled apoptosis in MCF-7 human breast cancer cells

31 March 2020

1 reference

Drug therapy: Bromocriptine

31 March 2020

1 reference

Galactorrhoea: Successful Treatment with Reduction of Plasma Prolactin Levels by Brom-ergocryptine

31 March 2020

1 reference

Drugs five years later. Bromocriptine

31 March 2020

1 reference

Diagnosis and management of hormone-secreting pituitary adenomas

31 March 2020

1 reference

Pergolide for the treatment of pituitary tumors secreting prolactin or growth hormone

31 March 2020

1 reference

Treatment of prolactin-secreting pituitary macroadenomas with the long-acting non-ergot dopamine agonist CV 205-502.

31 March 2020

1 reference

Cabergoline: an advance in dopaminergic therapy

31 March 2020

1 reference

Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment

31 March 2020

1 reference

A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group

31 March 2020

1 reference

Dimerization of the extracellular domain of the human growth hormone receptor by a single hormone molecule

31 March 2020

1 reference

Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly.

31 March 2020

1 reference

Receptor dimerization in GH and erythropoietin action--it takes two to tango, but how?

31 March 2020

1 reference

Treatment of Acromegaly with the Growth Hormone–Receptor Antagonist Pegvisomant

31 March 2020

1 reference

Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist

31 March 2020

1 reference

Primary medical therapy for acromegaly

31 March 2020

1 reference

Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells.

31 March 2020

1 reference

Suppression of rat and human growth hormone and prolactin secretion by a novel somatostatin/dopaminergic chimeric ligand.

31 March 2020

1 reference

Differential coupling with pertussis toxin-sensitive G proteins of dopamine and somatostatin receptors involved in regulation of adenohypophyseal secretion

31 March 2020

1 reference

Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity

31 March 2020

1 reference

15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma

31 March 2020

1 reference

Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice

31 March 2020

1 reference

Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas

31 March 2020

1 reference

PPAR-gamma receptor ligands: novel therapy for pituitary adenomas

31 March 2020

1 reference

Medical therapy of Cushing's disease

31 March 2020

1 reference

Retinoid target genes in acute promyelocytic leukemia

31 March 2020

1 reference

The biologic basis for the use of retinoids in cancer prevention and treatment

31 March 2020

1 reference

Retinoic acid prevents experimental Cushing syndrome

31 March 2020

1 reference

Effects of long-term treatment with the gonadotropin-releasing hormone analog nafarelin in patients with non-functioning pituitary adenomas

31 March 2020

1 reference

New approaches to treatment of various cancers based on cytotoxic analogs of LHRH, somatostatin and bombesin

31 March 2020

1 reference

Human pituitary tumor-transforming gene (PTTG1) motif suppresses prolactin expression

31 March 2020

1 reference

31 March 2020

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/NRC1320

1 reference

Dimensions Publication ID

9 August 2017

1030739436

0 references

1 reference